Research Report University Hospital for clinical assessment SGN35-014

Abstract

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Keywords

• CD30-positive Mature T-cell Lymphoma
• Brentuximab Vedotin